Kura Oncology, Inc. (NASDAQ: KURA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
9.47
+0.28+3.05%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -3.35 | Insider Own | 11.01% | Shs Outstand | 88.77M | Perf Week | 1.72% |
| Market Cap | 840.69M | Forward P/E | - | EPS next Y | -2.61 | Insider Trans | -1.02% | Shs Float | 86.00M | Perf Month | -14.22% |
| Enterprise Value | 283.69M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 15.97% | Perf Quarter | 2.38% |
| Income | -294.00M | P/S | 11.84 | EPS this Y | -4.14% | Inst Trans | - | Short Ratio | 7.72 | Perf Half Y | 14.51% |
| Sales | 71.00M | P/B | 7.78 | EPS next Y | 25.18% | ROA | -45.14% | Short Interest | 13.73M | Perf YTD | -8.85% |
| Book/sh | 1.22 | P/C | 1.45 | EPS next 5Y | - | ROE | -141.95% | 52W High | 12.49 -24.18% | Perf Year | 57.31% |
| Cash/sh | 6.54 | P/FCF | - | EPS past 3/5Y | - | ROIC | -57.53% | 52W Low | 5.45 73.76% | Perf 3Y | -5.02% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 94.66% | Volatility | 5.39% 5.07% | Perf 5Y | -48.78% |
| Dividend TTM | - | EV/Sales | 4.00 | EPS Y/Y TTM | -65.84% | Oper. Margin | -443.54% | ATR (14) | 0.53 | Perf 10Y | 121.26% |
| Dividend Ex-Date | - | Quick Ratio | 6.14 | Sales Y/Y TTM | 31.48% | Profit Margin | -411.19% | RSI (14) | 41.45 | Recom | 2.12 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.15 | EPS Q/Q | -25.76% | SMA20 | -9.46% | Beta | 0.38 | Target Price | 22.57 |
| Payout | 0.00% | Debt/Eq | 0.11 | Sales Q/Q | 28.57% | SMA50 | -6.66% | Rel Volume | 0.58 | Prev Close | 9.19 |
| Employees | 260 | LT Debt/Eq | 0.11 | Earnings | Aug 06 | SMA200 | -1.73% | Avg Volume | 1.74M | Price | 9.47 |
| IPO Date | Sep 16, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.54% -29.67% | Net Debt/EBITDA | 0.05 | Volume | 1,005,585 | Change | 3.05% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-15-26 | Reiterated | Bernstein | $24 | |
| Jun-04-26 | Reiterated | Wells Fargo | $24 | |
| Jun-04-26 | Reiterated | CLSA | $24 | |
| May-28-26 | Reiterated | Jefferies | Buy | $24 |
| May-28-26 | Reiterated | Oppenheimer | Outperform | $24 |
| Apr-14-26 | Initiated | Lake Street | Buy | $23 |
| Mar-13-26 | Reiterated | UBS | Buy | $14 → $15 |
| Jan-13-26 | Reiterated | Leerink Partners | Outperform | $20 |
| Nov-24-25 | Reiterated | Barclays | Overweight | $28 |
| Nov-14-25 | Reiterated | H.C. Wainwright | Buy | $32 |
Latest News
Jul-29-26
Jul-29-2607:06PM
Jul-27-26
Jul-27-2603:38PM
12:02PM
06:32AM
Jul-14-26
07:02AM
Jul-08-26
Jul-08-2607:23AM
Jul-03-26
Jul-03-2607:30AM
Jul-02-26
Jun-15-26
Jun-15-2609:59AM
Jun-13-26
Jun-13-2601:30AM
Jun-12-26
Jun-12-2607:02PM
Jun-11-26
Jun-11-2612:02PM
Company
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 71 | 67 | 54 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 4 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | 68 | 67 | 54 | -1 | 0 | 0 | 0 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 128 | 120 | 77 | 51 | 47 | 47 | 31 | 20 | 16 | |
| Research and Development | 260 | 251 | 170 | 115 | 93 | 85 | 60 | 48 | 47 | |
| Other Operating Expense | -2 | 0 | 0 | -1 | 0 | -1 | 1 | -1 | 0 | |
| Operating Income | -318 | -304 | -193 | -166 | -140 | -131 | -92 | -67 | -63 | |
| Interest Expense | 0 | 2 | 2 | 2 | 0 | 0 | 1 | 1 | 1 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 25 | 27 | 23 | 15 | 4 | 1 | 3 | 5 | 3 | |
| Net Income Before Taxes | -294 | -278 | -172 | -153 | -136 | -130 | -90 | -63 | -60 | |
| Income Taxes | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -294 | -279 | -174 | -153 | -136 | -130 | -90 | -63 | -60 | |
| Net Income From Continuing Operations | -294 | -279 | -174 | -153 | -136 | -130 | -90 | -63 | -60 | |
| Net Income | -294 | -279 | -174 | -153 | -136 | -130 | -90 | -63 | -60 | |
| EPS (Recurring) | -3.35 | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | -1.51 | -1.72 | |
| EPS (Basic, Before Extraordinaries) | -3.35 | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | -1.51 | -1.72 | |
| EPS (Diluted) | -3.35 | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | -1.51 | -1.72 | |
| EBITDA | -293 | -276 | -169 | -150 | -135 | -129 | -89 | -67 | -63 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 11.87 | 13.65 | 13.87 | — | — | — | — | — | — | |
| Gross Margin | 95.77 | 100.00 | 100.00 | — | — | — | — | — | — | |
| Operating Margin | -447.89 | -453.73 | -357.41 | — | — | — | — | — | — | |
| Net Margin | -414.08 | -416.42 | -322.22 | — | — | — | — | — | — | |
| Shares Outstanding | 89 | 88 | 86 | 73 | 67 | 66 | 53 | 42 | 35 | |
| Market Capitalization | 843 | 914 | 749 | 1,050 | 831 | 924 | 1,731 | 578 | 491 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Leoni Mollie | Chief Medical Officer | Jun 18 '26 | Sale | 9.82 | 84,929 | 834,283 | 182,345 | Jun 22 |
| Powl Brian T. | Chief Commercial Officer | May 21 '26 | Sale | 11.00 | 10,000 | 110,000 | 173,614 | May 22 |
| FORD KATHLEEN | Chief Operating Officer | May 19 '26 | Sale | 9.08 | 2,257 | 20,483 | 153,560 | May 20 |
| Powl Brian T. | Chief Commercial Officer | May 19 '26 | Sale | 9.21 | 339 | 3,122 | 183,614 | May 20 |
| Bair Teresa Brophy | Chief Legal Officer | May 18 '26 | Sale | 9.38 | 2,256 | 21,160 | 226,931 | May 20 |
| WILSON TROY EDWARD | President and CEO | Mar 23 '26 | Option Exercise | 6.15 | 12,206 | 75,066 | 435,456 | Mar 25 |
| Malley Thomas | Director | Mar 18 '26 | Option Exercise | 3.12 | 20,000 | 62,400 | 10,000 | Mar 20 |
| Bair Teresa Brophy | Chief Legal Officer | Jan 27 '26 | Sale | 8.46 | 11,208 | 94,828 | 226,931 | Jan 27 |
| Powl Brian T. | Chief Commercial Officer | Jan 27 '26 | Sale | 8.46 | 6,414 | 54,266 | 183,275 | Jan 27 |
| FORD KATHLEEN | Chief Operating Officer | Jan 27 '26 | Sale | 8.46 | 1,813 | 15,339 | 153,560 | Jan 27 |
| Leoni Mollie | Chief Medical Officer | Jan 27 '26 | Sale | 8.46 | 8,180 | 69,209 | 267,274 | Jan 27 |
| DOYLE THOMAS JAMES | SVP, Finance & Accounting | Jan 27 '26 | Sale | 8.46 | 7,142 | 60,427 | 145,167 | Jan 27 |
| Burrows Francis | Chief Scientific Officer | Jan 27 '26 | Sale | 8.46 | 1,311 | 11,092 | 32,424 | Jan 27 |
| Burrows Francis | Chief Scientific Officer | Dec 18 '25 | Option Exercise | 4.80 | 35,000 | 168,000 | 57,461 | Dec 19 |
| Burrows Francis | Chief Scientific Officer | Dec 18 '25 | Sale | 9.78 | 23,726 | 231,931 | 33,735 | Dec 19 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.